Compare Alcon AG (ALC) vs Nu Holdings Ltd (NU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Nu Holdings Ltd — how do they compare? Alcon AG trades at $66.77 (market cap $32.69B), while Nu Holdings Ltd trades at $13.41 (market cap $65.74B). The key difference: Nu Holdings Ltd is far larger — about 2× Alcon AG's market cap, and Alcon AG pays a 0.54% dividend while Nu Holdings Ltd pays none. Which is the better fit depends on your goals.
| ALC | NU | |
|---|---|---|
Market Cap | $32.69B | $65.74B |
Sector | Health | Financials |
52-Week High | $92.22 | $18.76 |
52-Week Low | $62.02 | $11.60 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
NU stock trades at $13.61, showing no change in the last 24 hours. The technical outlook is bullish based on moving averages, with key support at $13 and resistance at $14. Fundamentally, the company demonstrates robust growth, with revenue increasing from $3.0B in 2022 to $10.63B in 2025 and net income turning positive to $2.87B. Recent earnings show mixed results, with a beat in Q3 2025 but misses in Q4 2025 and Q1 2026 against expectations.
The investment outlook is positive, supported by strong analyst consensus with a $14.98 price target and 55% buy ratings. Key opportunities include expansion in Latin America and a high return on equity of 30.04%. Risks involve recent earnings misses, competitive pressures, and macroeconomic volatility in emerging markets. The stock presents a growth opportunity but requires monitoring of execution and regional economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
